{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:59:28Z","timestamp":1781362768804,"version":"3.54.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.8084","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T22:45:51Z","timestamp":1619649951000},"page":"e218084","source":"Crossref","is-referenced-by-count":27,"title":["Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials"],"prefix":"10.1001","volume":"4","author":[{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[{"name":"Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Koehn","sequence":"additional","affiliation":[{"name":"Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Divisions of Hematology & Medical Oncology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"issue":"5","key":"zoi210259r1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.v95.5","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"zoi210259r2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi210259r3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"zoi210259r4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"zoi210259r5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/annonc\/mdy116","article-title":"When is crossover desirable in cancer drug trials and when is it problematic?","volume":"29","author":"Haslam","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi210259r6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrclinonc.2017.72","article-title":"Combining drugs and extending treatment\u2014a PFS end point is not sufficient.","volume":"14","author":"Gyawali","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"zoi210259r7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi210259r8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"suppl 1","key":"zoi210259r9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-134847","article-title":"Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 MAIA Study.","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"issue":"10218","key":"zoi210259r10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"zoi210259r11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1182\/blood.V118.21.476.476","article-title":"Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial.","volume":"118","author":"San Miguel","year":"2011","journal-title":"Blood."},{"issue":"19","key":"zoi210259r12","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi210259r13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi210259r14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"zoi210259r15","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood-2019-123527","article-title":"Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four-year update of CASTOR.","volume":"134","author":"Weisel","year":"2019","journal-title":"Blood"},{"issue":"12","key":"zoi210259r16","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"zoi210259r17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-020-00948-5","article-title":"Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.","volume":"13","author":"Weisel","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7","key":"zoi210259r18","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"zoi210259r19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi210259r20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1200\/JOP.0714701","article-title":"Prepare and plan for financial constraints on clinical trials.","volume":"3","year":"2007","journal-title":"J Oncol Pract"},{"issue":"17","key":"zoi210259r21","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma.","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi210259r22","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014.","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"zoi210259r23","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"zoi210259r24","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.","author":"Dimopoulos","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"zoi210259r25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"14","key":"zoi210259r27","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi210259r28","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"zoi210259r29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"zoi210259r30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"issue":"4","key":"zoi210259r31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/1740774514527651","article-title":"Introduction to dynamic treatment strategies and sequential multiple assignment randomization.","volume":"11","author":"Lavori","year":"2014","journal-title":"Clin Trials"},{"key":"zoi210259r26","unstructured":"Daratumumab, VELCADE (bortezomib), lenalidomide and dexamethasone compared to VELCADE, lenalidomide and dexamethasone in subjects with previously untreated multiple myeloma. ClinicalTrials.gov Identifier: NCT03710603. Updated July 21, 2020. Accessed December 15, 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03710603"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2779248\/mohyuddin_2021_oi_210259_1618847995.71266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T22:46:00Z","timestamp":1619649960000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2779248"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8084","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]}}}